PCJ Stock Overview
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Abeona Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.40 |
| 52 Week High | US$8.06 |
| 52 Week Low | US$2.88 |
| Beta | 1.51 |
| 11 Month Change | -10.74% |
| 3 Month Change | 6.93% |
| 1 Year Change | 40.85% |
| 33 Year Change | -62.66% |
| 5 Year Change | -92.80% |
| Change since IPO | -95.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| PCJ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.9% | -0.7% | 0.2% |
| 1Y | 40.8% | -17.2% | 8.5% |
Return vs Industry: PCJ exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: PCJ exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| PCJ volatility | |
|---|---|
| PCJ Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: PCJ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: PCJ's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 84 | Vish Seshadri | www.abeonatherapeutics.com |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
Abeona Therapeutics Inc. Fundamentals Summary
| PCJ fundamental statistics | |
|---|---|
| Market cap | €250.34m |
| Earnings (TTM) | -€68.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.7x
P/E RatioIs PCJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCJ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$23.54m |
| Gross Profit | -US$23.54m |
| Other Expenses | US$47.49m |
| Earnings | -US$71.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 40.7% |
How did PCJ perform over the long term?
See historical performance and comparison